Anixa cuts costs, $16M cash as CAR‑T and vaccine Phase 1 trials advance; pre‑revenue

Anixa Biosciences, Inc. (NASDAQ: ANIX)

Quick take: Anixa remains a pre-revenue biotech advancing cancer vaccines and a CAR‑T therapeutic. The company cut operating spending versus prior periods and retains roughly $16.0M in cash and short‑term investments, but continues to report operating losses and an increasing accumulated deficit while burning cash from operations.

Key facts & stats
- Revenue: $0 for the three and nine months ended July 31, 2025.
- Net loss: $(2,280)k for Q3 (three months ended July 31, 2025); $(8,306)k for nine months ended July 31, 2025.
- Loss per share (basic & diluted): $(0.07) for the quarter; $(0.25) for nine months.
- Weighted average shares outstanding: 32,476 (Q) / 32,293 (9M).
- Shares outstanding: 32,916,915 as of September 10, 2025 (report disclosure).
- Cash and cash equivalents: $1,495k; Short‑term investments: $14,534k; Total cash + ST investments: $16,029k at July 31, 2025.
- Total assets: $17,651k; Total liabilities: $2,240k; Total equity: $15,411k (includes noncontrolling interest $(1,184)k).
- Operating cash used: $(5,918)k for nine months ended July 31, 2025.
- Short‑term investments down from $18,653k (Oct 31, 2024) to $14,534k (Jul 31, 2025).
- R&D expense (Q): $1,055k (Q) vs $1,925k prior‑year Q; R&D (9M): $3,929k vs $4,920k prior year.
- G&A expense (Q): $1,381k vs $1,667k prior‑year Q; G&A (9M): $4,896k vs $5,748k prior year.
- Non‑cash stock‑based compensation: $855k (Q); $2,899k (9M).
- Stock options outstanding (2018 plan): 12,476,094 (options exercisable 8,943,235).
- Warrants outstanding: 300,000 at $6.56 expiring March 22, 2026.
- ATM financing: raised $1,924k net (611,686 shares) in 9M 2025; ATM capacity remaining ~ $95M.

What's happening inside the company
- Clinical progress: CAR‑T (Certainty Therapeutics subsidiary) is in a Phase 1 dose‑escalation trial; the company treated patients up to a 30x dose cohort with treatments described as "well‑tolerated" and some anecdotal signs of efficacy (T‑cell infiltration, tumor necrosis).
- Vaccine programs: Breast cancer vaccine Phase 1 completed enrollment and follow‑ups; final Phase 1 data expected at San Antonio Breast Cancer Symposium in December 2025 and a Phase 2 neo‑adjuvant trial is being prepared. Ovarian vaccine work continues with NCI PREVENT support.
- Funding & structure: Management says current cash + investments should fund operations at least 12 months; business model emphasizes external collaborations and milestone/licensing potential. Wistar holds ~4.1% of Certainty (noncontrolling interest).

Income statement - Positives
- Operating costs are down: total operating expenses decreased to $2,436k (Q) from $3,592k prior‑year Q and $8,825k (9M) vs $10,668k prior year - showing cost control.
- R&D focus retained: R&D remains the largest expense but decreased, reflecting lower outside R&D spend and completed/waning trial activities in some areas.
- Non‑cash compensation is a sizable portion of expense (reduces cash burn when excluded): operating costs ex‑stock comp were $1,581k (Q) and $5,926k (9M), materially lower than GAAP totals.
- Liquidity: $16.0M in cash + short‑term investments and access to ATM program (~$95M capacity) provide financing optionality.

Income statement - Negatives / risks
- No revenue: still zero revenue from therapeutics or vaccines; company is pre‑revenue and dependent on future licensing, milestones or financings.
- Continued losses: meaningful net losses remain-$(8,306)k YTD and accumulated deficit of $(248,982)k as of July 31, 2025.
- Cash burn: $(5,918)k used in operations in nine months - cash balance + investments declined ~$3.895M year‑to‑date; ongoing trials and development may prolong cash depletion.
- Funding dilution risk: ATM and large outstanding option pools (millions of options) create potential future dilution if exercised or used for capital raises.
- Lower interest income: investment income dropped (interest income $519k YTD vs $883k prior YTD) as yields and invested balances fell, reducing passive income support.

Bottom line: Anixa is advancing promising early clinical programs (CAR‑T and cancer vaccines) and has reduced cash outflows versus prior year, but remains pre‑revenue with ongoing losses and cash burn. The near‑term investment case depends on clinical readouts (Phase 1 final data in Dec 2025) and the company's ability to extend runway through partnerships, milestone payments or additional equity raises.